Due partly to a lack of specific c-Src inhibitors suitable for clinical use, identifying the effectors and downstream processes through which c-Src drives breast cancer progression may be a more promising therapeutic strategy than directly targeting c-Src itself. This evidence concerns the gene SRC and breast carcinoma.